EUVIMEDEUVIMED entdecken
Crossref

Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study

Yating Wang iD, Kyle Kondrat, Janak Adhikari, Quynh Nguyen iD, Qian Yu iD, Dipesh Uprety iD

Cancer · 2025-01 · 131 (1)

DOI: 10.1002/cncr.35476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 10.07.2024. Verfasst von Yating Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology, Ascension Providence Hospital, Southfield, Michigan, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, SEER Program. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2015, the US Food and Drug Administration approved nivolumab as the first immunotherapy for patients with advanced non–small cell lung cancer (NSCLC). However, population‐based survival benefit studies after the introduction of immunotherapy in lung cancer are lacking. This study examined overall survival (OS) and cancer‐specific survival in patients with NSCLC in the pre immunotherapy and immunotherapy eras.

Methods

This study used the Surveillance, Epidemiology, and End Results database, which spanned 17 registries from 2000 to 2020. Two cohorts were delineated: preimmunotherapy (2010–2014) and immunotherapy (2015–2020), which coincided with nivolumab’s approval.

Results

This study included 191,802 patients, 90,807 in the preimmunotherapy era and 100,995 in the immunotherapy era. OS was significantly higher in the immunotherapy era, as shown by Kaplan–Meier curves (1‐year OS, 40.1% vs. 33.5%; 3‐year OS, 17.8% vs. 11.7%; 5‐year OS, 10.7% vs. 6.8%; median OS, 8 vs. 7 months; p < .001 by log‐rank test). Similarly, cancer‐specific survival improved in the immunotherapy era (1‐year survival, 44.0% vs. 36.8%; 3‐year survival, 21.7% vs. 14.4%; 5‐year survival, 14.3% vs. 9.0%; median OS, 10 vs. 8 months; p < .001 by log‐rank test). Survival rates were significantly better in the immunotherapy era, as confirmed by multivariate analysis with a Cox proportional hazards model after adjusting for age, sex, race, income, and geographical area (adjusted hazard ratio, 0.830; 95% CI, 0.821–0.840; p < .001).

Conclusions

In summary, the survival rate of patients with metastatic NSCLC has improved since the introduction of immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapySEER ProgramHumansMaleUnited StatesFemaleAgedMiddle AgedNivolumabAdultKaplan-Meier EstimateAged, 80 and overDrug Approval

Stichwörter der Autor:innen

immunotherapymetastatic non–small cell lung cancer (NSCLC)population studysurvival trend

Substanzen

Nivolumab

Autor:innen und Institutionen

  • Hematology and Oncology, Ascension Providence Hospital, Southfield, Michigan, USA.
  • Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Internal Medicine, Northernlight Eastern Maine Medical Center, Bangor, Maine, USA.
  • Internal Medicine, Logan Regional Medical Center, Logan, West Virginia, USA.
  • Interventional Radiology, University of Chicago Medical Center, Chicago, Illinois, USA.

ORCID-Profile: Yating Wang, Quynh Nguyen, Qian Yu, Dipesh Uprety

Zitieren

APA

Wang, Y., Kondrat, K., Adhikari, J., Nguyen, Q., Yu, Q., & Uprety, D. (2025). Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study. Cancer, 131(1). https://doi.org/10.1002/cncr.35476

Vancouver

Wang Y, Kondrat K, Adhikari J, Nguyen Q, Yu Q, Uprety D. Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study. Cancer. 2025;131(1). doi:10.1002/cncr.35476

BibTeX
@article{Wang2025,
  author = {Wang, Yating and Kondrat, Kyle and Adhikari, Janak and Nguyen, Quynh and Yu, Qian and Uprety, Dipesh},
  title = {Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {1},
  doi = {10.1002/cncr.35476}
}
Kostenlos starten →